The RSSearch® Registry is an international multi-year database designed to track SRS/SBRT (Stereotactic Radiosurgery/Stereotactic Body Radiation Therapy) utilization, treatment practices and outcomes to help determine, over time, the most effective use of these systems in management of patients with life threatening tumors and other diseases. (This study was formally called ReCKord and included the CyberKnife only; The ReCKord study continues as a CyberKnife subset of RSSearch.)
The Registry is designed to help SRS/SBRT (Stereotactic Radiosurgery/Stereotactic Body Radiation Therapy) users to understand utilization of and key treatment outcomes for these treatment approaches. Some of the objectives include: Allow participants to record information about usage of SRS/SBRT in everyday practice, including patient characteristics and disease information, treatment plans and outcomes Provide participants with ready access to data for publication of their own experience and as a tool for establishing collaborations with other participating sites Facilitate quality improvement efforts for individual treatment providers Understand the effectiveness of different treatment plans for different types of lesions, diseases and treatments The Registry tracks select outcomes for each condition treated by SRS/SBRT (for example, PSA for prostate cancer); the Registry also provides individual participants the ability to add additional outcomes for each and any condition of specific interest to their institutions. The Registry is hosted by Vision Tree, Inc who is an independent vendor of electronic registries; they are responsible for HIPAA compliance, including all security mechanisms. Patients will be enrolled prospectively. Some retrospective patient data is likely to be included in order to capture both short and longer term outcomes data.
Study Type
OBSERVATIONAL
Enrollment
50,000
Intervention varies by condition being treated.
Penrose Cancer Center
Colorado Springs, Colorado, United States
ENROLLING_BY_INVITATIONSylvester Comprehensive Cancer Center, University of Miami
Miami, Florida, United States
RECRUITINGSoutheast Georgia Health System
Brunswick, Georgia, United States
ENROLLING_BY_INVITATIONHenry Ford Health System
Detroit, Michigan, United States
RECRUITINGAtlantiCare Regional Medical Center and AtlantiCare Cancer Care Institute
Egg Harbor, New Jersey, United States
ENROLLING_BY_INVITATIONRiverview Medical Center
Red Bank, New Jersey, United States
ENROLLING_BY_INVITATIONNJ Cyberknife at Community Medical Center
Toms River, New Jersey, United States
ENROLLING_BY_INVITATIONMontefiore Medical Center
The Bronx, New York, United States
ENROLLING_BY_INVITATIONGeisinger Health System
Danville, Pennsylvania, United States
ENROLLING_BY_INVITATIONPhiladelphia CyberKnife
Philadelphia, Pennsylvania, United States
ENROLLING_BY_INVITATION...and 3 more locations
Overall survival
Survival from time of treatment to death
Time frame: Up to 5 years
Local and distant recurrence
Calculated from time of treatment to recurrence
Time frame: One to Five years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.